Topline results were announced from a phase 3 trial evaluating linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).

PBC patients receiving linerixibat saw statistically significant improvement in cholestatic pruritus - or relentless itch.

The GLISTEN study evaluating GSK's candidate, linerixibat, for treating cholestatic pruritus related to primary biliary cholangitis meets the primary endpoint.

GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC: London, UK Wednesday, Novembe ...

GSK’s linerixibat helped reduce itch in patients with a rare bile duct disease, meeting its primary endpoint in a late-stage ...

GSK's phase 3 GLISTEN trial demonstrated linerixibat's potential to treat relentless itch in PBC patients, meeting its ...

GSK (NYSE:GSK) said a Phase 3 study of its drug linerixibat in the treatment of relentless itching in patients with primary biliary cholangitis, or PBC, met its primary endpoint. The U.K. drugmaker ...

Some healthcare advocacy groups launched a "Stop RFK War Room" to fight Robert F. Kennedy Jr.'s nomination for HHS Secretary.

UK pharma major GSK today announced positive headline results of GLISTEN, the ongoing global Phase III clinical trial ...

Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...

Drugmaker GSK said on Tuesday that its linerixibat candidate had shown "positive" Phase III results in cholestatic pruritus ...

The GSK share price has been in a strong freefall after peaking at 1,785p in September. Most recently, the GSK stock ...